BERG's platform combines patient biology and artificial intelligence-based analytics to engage the differences between healthy and disease environments. The patient’s own biology drives the platform’s results, guiding the discovery and development of drugs, diagnostics and healthcare applications.
The platform utilizes patient population health data, with the aim of promoting faster discovery and development of treatments, and more effective precision treatments.
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze